Pliva is the largest company by turnover in central and eastern Europe, while Helm AG is a leading multi-functional organisation for international marketing in chemicals, active pharmaceutical ingredients and fertilisers. Company officials said that an alliance for marketing formulations with a South African company was also on the cards. The agreement will be signed shortly, even as Kopran has already filed 14 product dossiers there, officials added.
The market for bulk roxythromycin in the European Union, according to rough estimates, is around 35 MT (metric tonne) with a growth rate of 20 per cent. Kopran expects to sell 12 MT of bulk roxythromycin in the first year, officials said.
The company has filed DMF (drug master file) for roxythromycin and the drug is scheduled to go off-patent in France by August 2003, analysts said. The company has already written off close to Rs 28 crore, which it had lent to Ketan Parekh, from its books and raised an equivalent amount by way of a rights issue.
The company has plans to enter the regulated US markets and expects to double its profit and turnover in the next three years. It is open to small acquisitions and is not depending too much on organic growth, sources said.
Company officials were silent on the proposed merger of Kopran Ltd with Kopran Pharmaceuticals, which is pending in the high court for close to 18 months.